2017 Fiscal Year Final Research Report
Novel antitumor immunotherapy via immune reconstitution after chemotherapy for advanced lung cancer
| Project/Area Number |
15K09168
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
各務 博 埼玉医科大学, 医学部, 教授 (30418686)
吉澤 弘久 新潟大学, 医歯学総合病院, 特任教授 (50282984)
三浦 理 新潟大学, 医歯学総合病院, その他 (70420320)
中田 光 新潟大学, 医歯学総合病院, 教授 (80207802)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 免疫療法 / PD-1 / T細胞 |
|---|
| Outline of Final Research Achievements |
We previously reported that the induction of effector T cells was enhanced during immune reconstitution after chemotherapy. In the current study, we found that antitumor effects of anti-PD-1 therapy was augmented when combined with immune reconstitution mediated by chemotherapy. This enhancement of anti-PD-1 therapy was observed even in PD-L1 negative tumors. FACS analyses revealed that PD-L1 was expressed on tumor-infiltration immune cells. These findings indicated that effector T cells were suppressed by PD-L1 expressed on tumor-infiltration immune cells.
|
| Free Research Field |
呼吸器内科学分野
|
